Anlotinib (AL3818) is a multi‐TKI that is designed to inhibit VEGFR1‐3, FGFR1‐4, PDGFRα/β, c‐Kit and Ret and has been approved by the CFDA as a third‐line or beyond therapy for stage IV NSCLC in 2018.142. The gene discussed is RET; the disease is non-small cell lung carcinoma.